Adaptimmune Therapeutics Plc, a gene-therapy company that employs around 100 at its Navy Yard headquarters and 200 in Oxford, England, said it had raised $100 million through a sale of American Depository Shares on the Nasdaq stock market.

Adaptimmune alters T-cells to fight cancer. With WuXi AppTech, TNunity and Spark Therapeutics, it is one of several Philly firms racing to make profitable gene therapies.

"Adaptimmune intends to use the net proceeds from this offering to advance the company's wholly-owned pipeline of SPEAR T-cell candidates through clinical trials as well as for other general corporate purposes," the company said in a statement.

More on Adaptimmune and its Philadelphia facilities at http://www.philly.com/philly/business/pharma/Adaptimmune-opens-US-headquarters-at-the-Navy-Yard-to-develop-cancer-therapies.html?arc404=true&mobi=true